ATRAAtara Biotherapeutics, Inc.
Earnings
When Atara Biotherapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
53 quarters. Sep 30, 2013 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Mar 15, after the close
Mon, Mar 15, 2027in 117 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 23 – Mar 19
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $1.60M
- Revenue, change from a year earlier: Q3 2026 −64.6%, Q2 2026 −96.4%, Q1 2026 −99.5%, Q4 2025 −95.1%
- Net income
- -$3.41M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- $1.22M
- −64.6%
- Net income
- -$2.23M
- N/M
- EPS
- -$0.15
- N/M
- Revenue
- $630.00K
- −96.4%
- Net income
- -$4.83M
- N/M
- EPS
- -$0.32
- N/M
- Revenue
- $516.00K
- −99.5%
- Net income
- -$4.15M
- N/M
- EPS
- -$0.29
- N/M
- Revenue
- $1.60M
- −95.1%
- Net income
- -$3.41M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 10, 2026 · after-hours | Nov 10, 2026 | 41 d | 10-Q | $1.22M | −64.6% | -$0.15 | 0.4% | |
| Q2 2026 | Jun 30, 2026 | Aug 12, 2026 · after-hours | Aug 12, 2026 | 43 d | 10-Q | $630.00K | −96.4% | -$0.32 | 6.0% | |
| Q1 2026 | Mar 31, 2026 | — | May 12, 2026 | 42 d | 10-Q | $516.00K | −99.5% | -$0.29 | +6.8% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Mar 16, 2026 · after-hours | Mar 16, 2026 | 75 d | 10-K | $1.60M | −95.1% | — | 10.9% | |
| Q3 2025 | Sep 30, 2025 | Nov 11, 2025 · after-hours | Nov 12, 2025 | 43 d | 10-Q | $3.45M | −91.4% | -$0.32 | 0.4% | |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 · after-hours | Aug 11, 2025 | 42 d | 10-Q | $17.58M | −38.6% | $0.19 | +7.5% | |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 · after-hours | May 15, 2025 | 45 d | 10-Q | $98.15M | +258.8% | $3.50 | +14.9% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 7, 2025 · after-hours | Mar 7, 2025 | 66 d | 10-K | $32.75M | +670.3% | — | 8.6% | |
| Q3 2024 | Sep 30, 2024 | Nov 12, 2024 · after-hours | Nov 12, 2024 | 43 d | 10-Q | $40.19M | +1,779.8% | -$2.93 | +22.9% | |
| Q2 2024 | Jun 30, 2024 | Aug 12, 2024 · after-hours | Aug 12, 2024 | 43 d | 10-Q | $28.64M | +2,892.7% | -$3.10 | — | |
| Q1 2024 | Mar 31, 2024 | May 9, 2024 · after-hours | May 9, 2024 | 39 d | 10-Q | $27.36M | +2,131.4% | -$5.65 | +10.9% | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Mar 27, 2024 · after-hours | Mar 28, 2024 | 88 d | 10-K | $4.25M | +1,824.0% | — | +3.6% | |
| Q3 2023 | Sep 30, 2023 | Oct 31, 2023 · after-hours | Nov 1, 2023 | 32 d | 10-Q | $2.14M | −52.1% | -$16.40 | — | |
| Q2 2023 | Jun 30, 2023 | Aug 8, 2023 · after-hours | Aug 8, 2023 | 39 d | 10-Q | $957.00K | −98.1% | -$16.91 | — | |
| Q1 2023 | Mar 31, 2023 | May 8, 2023 · after-hours | May 8, 2023 | 38 d | 10-Q | $1.23M | −83.2% | -$0.72 | 17.8% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Feb 8, 2023 · after-hours | Feb 8, 2023 | 39 d | 10-K | $221.00K | — | — | — | |
| Q3 2022 | Sep 30, 2022 | Nov 8, 2022 · after-hours | Nov 8, 2022 | 39 d | 10-Q | $4.46M | — | -$0.82 | 18.0% | |
| Q2 2022 | Jun 30, 2022 | Aug 8, 2022 · after-hours | Aug 8, 2022 | 39 d | 10-Q | $51.58M | — | $0.18 | — | |
| Q1 2022 | Mar 31, 2022 | May 5, 2022 · after-hours | May 5, 2022 | 35 d | 10-Q | $7.31M | — | -$0.87 | +1.5% | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Feb 28, 2022 · after-hours | Feb 28, 2022 | 59 d | 10-K | — | — | — | 26.8% | |
| Q3 2021 | Sep 30, 2021 | Nov 3, 2021 · after-hours | Nov 4, 2021 | 35 d | 10-Q | — | — | -$0.90 | +28.5% | |
| Q2 2021 | Jun 30, 2021 | Aug 9, 2021 · after-hours | Aug 9, 2021 | 40 d | 10-Q | — | — | -$0.91 | — | |
| Q1 2021 | Mar 31, 2021 | May 4, 2021 · after-hours | May 4, 2021 | 34 d | 10-Q | — | — | -$0.86 | — | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | Mar 1, 2021 · after-hours | Mar 1, 2021 | 60 d | 10-K | — | — | — | 6.8% | |
| Q3 2020 | Sep 30, 2020 | Nov 9, 2020 · after-hours | Nov 9, 2020 | 40 d | 10-Q | — | — | -$0.92 | +30.0% | |
| Q2 2020 | Jun 30, 2020 | Aug 5, 2020 · after-hours | Aug 5, 2020 | 36 d | 10-Q | — | — | -$1.14 | — | |
| Q1 2020 | Mar 31, 2020 | May 6, 2020 · after-hours | May 6, 2020 | 36 d | 10-Q | — | — | -$1.20 | +19.3% | |
| FY 2019 | ||||||||||
| Q4 2019derived | Dec 31, 2019 | Feb 26, 2020 · after-hours | Feb 27, 2020 | 58 d | 10-K | — | — | — | +2.6% | |
| Q3 2019 | Sep 30, 2019 | Nov 6, 2019 · after-hours | Nov 7, 2019 | 38 d | 10-Q | — | — | -$1.31 | — | |
| Q2 2019 | Jun 30, 2019 | Aug 7, 2019 · after-hours | Aug 8, 2019 | 39 d | 10-Q | — | — | -$1.60 | +4.2% | |
| Q1 2019 | Mar 31, 2019 | May 8, 2019 · after-hours | May 9, 2019 | 39 d | 10-Q | — | — | -$1.44 | — | |
| FY 2018 | ||||||||||
| Q4 2018derived | Dec 31, 2018 | Feb 25, 2019 · after-hours | Feb 26, 2019 | 57 d | 10-K | — | — | — | 10.7% | |
| Q3 2018 | Sep 30, 2018 | Nov 5, 2018 · after-hours | Nov 6, 2018 | 37 d | 10-Q | — | — | -$1.29 | 0.9% | |
| Q2 2018 | Jun 30, 2018 | Jul 31, 2018 · after-hours | Aug 1, 2018 | 32 d | 10-Q | — | — | -$1.15 | 2.1% | |
| Q1 2018 | Mar 31, 2018 | May 7, 2018 · after-hours | May 8, 2018 | 38 d | 10-Q | — | — | -$1.05 | — | |
| FY 2017 | ||||||||||
| Q4 2017derived | Dec 31, 2017 | Feb 26, 2018 · after-hours | Feb 27, 2018 | 58 d | 10-K | — | — | — | 13.7% | |
| Q3 2017 | Sep 30, 2017 | — | Nov 9, 2017 | 40 d | 10-Q | — | — | — | 6.3% | |
| Q2 2017 | Jun 30, 2017 | — | Aug 7, 2017 | 38 d | 10-Q | — | — | — | 4.8% | |
| Q1 2017 | Mar 31, 2017 | — | May 4, 2017 | 34 d | 10-Q | — | — | — | 14.2% | |
| FY 2016 | ||||||||||
| Q4 2016derived | Dec 31, 2016 | — | Mar 9, 2017 | 68 d | 10-K | — | — | — | +8.4% | |
| Q3 2016 | Sep 30, 2016 | — | Nov 4, 2016 | 35 d | 10-Q | — | — | — | +17.2% | |
| Q2 2016 | Jun 30, 2016 | — | Aug 8, 2016 | 39 d | 10-Q | — | — | — | 9.4% | |
| Q1 2016 | Mar 31, 2016 | — | May 6, 2016 | 36 d | 10-Q | — | — | — | +8.9% | |
| FY 2015 | ||||||||||
| Q4 2015derived | Dec 31, 2015 | — | Mar 4, 2016 | 64 d | 10-K | — | — | — | +2.5% | |
| Q3 2015 | Sep 30, 2015 | — | Nov 6, 2015 | 37 d | 10-Q | — | — | — | +9.5% | |
| Q2 2015 | Jun 30, 2015 | — | Aug 7, 2015 | 38 d | 10-Q | — | — | — | 11.9% | |
| Q1 2015 | Mar 31, 2015 | — | — | — | — | — | — | — | — | |
| FY 2014 | ||||||||||
| Q4 2014derived | Dec 31, 2014 | — | — | — | — | — | — | — | — | |
| Q3 2014 | Sep 30, 2014 | — | — | — | — | — | — | — | — | |
| Q2 2014 | Jun 30, 2014 | — | — | — | — | — | — | — | — | |
| Q1 2014 | Mar 31, 2014 | — | — | — | — | — | — | — | — | |
| FY 2013 | ||||||||||
| Q4 2013derived | Dec 31, 2013 | — | — | — | — | — | — | — | — | |
| Q3 2013 | Sep 30, 2013 | — | — | — | — | — | — | — | — | |
Earlier years, FY 2013 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR